Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis Corp (CSE: IMCC, NASDAQ: IMCC) has rescheduled the release of its operational and financial results for Q4 and the full year ended December 31, 2021, to March 31, 2022, before market open. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results, with an opportunity for Q&A. IM Cannabis operates in international markets including Israel, Canada, and Germany, focusing on premium cannabis products for both medical and recreational consumers.
IM Cannabis Corp (CSE: IMCC, NASDAQ: IMCC) will release its fourth quarter and full year 2021 financial results on March 30, 2022, before market open. A conference call will follow at 9:00 a.m. ET to discuss these results, with dial-in options for U.S., Canada, Israel, Germany, and international participants. IM Cannabis operates in Israel, Germany, and Canada, focusing on premium cannabis products for both medical and recreational markets.
IM Cannabis Corp (CSE: IMCC, NASDAQ: IMCC) has finalized three strategic acquisitions to bolster its operations in Israel, Canada, and Germany. These transactions include Vironna, a top cannabis dispensing entity, Pharm Yarok, a leading pharmacy, and Panaxia, which provides vital distribution licenses. The total value of these acquisitions amounts to approximately NIS 39.1 million (around $15.2 million). CEO Oren Shuster emphasized the importance of these moves for the company’s expansion and operational efficiency, highlighting an increase in customer satisfaction and consumption levels.
IM Cannabis Corp (NASDAQ: IMCC) reported preliminary financial results for Q4 and fiscal year 2021, with Q4 revenues exceeding $20 million, up over 37% from Q3 2021 and 308% year-over-year. For FY 2021, revenues reached at least $54 million, representing a 240% increase from FY 2020. The Q4 gross margin was approximately 18%, influenced by investments in Germany and COVID-19 impacts in Canada. The company plans to launch the WAGNERS brand in Germany and has signed an agreement to acquire Oranim, enhancing its position in the Israeli market.
IM Cannabis Corp. (NASDAQ: IMCC) has engaged MZ Group to enhance its investor relations and financial communications strategy. This collaboration aims to boost the company’s visibility and support its expansion in the global cannabis industry. MZ Group will assist in executing a comprehensive capital markets strategy, coordinating investor roadshows, and enhancing brand awareness. The agreement, initiated on February 1, 2022, includes a monthly fee of $14,000 and potential share issuance if it remains effective past August 1, 2022. IM Cannabis is operational across Israel, Canada, and Germany.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announces that Focus Medical has imported approximately 399 kg of premium Canadian cannabis from its subsidiary, TJAC. The product will be launched in the Israeli medical market by Q1 2022 under the WAGNERS brand, which holds a 5.6% market share in Ontario. CEO Oren Shuster highlights the achievement as a key milestone in the company's strategy, emphasizing the robust global supply chain and increasing demand for premium cannabis. This import is anticipated to be part of a consistent supply going forward.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) has announced managerial changes, including the appointment of Rinat Efrima as CEO of IMC Holdings, the company's Israeli subsidiary. Efrima, previously with Caesarstone and Kimberly-Clark, will focus on integrating recent acquisitions and driving growth. Yael Harrosh has been promoted to Chief Legal and Operations Officer, overseeing compliance and operations in the cannabis sector. These changes aim to strengthen leadership and enhance operational execution amid expansion in the Israeli market.
IM Cannabis plans to debut its WAGNERS brand in Germany's medical cannabis market in 2022, subject to regulatory approval. With expectations of strong demand for premium indoor-grown cannabis, the company is expanding its presence in one of the largest medical cannabis markets globally. The completion of a state-of-the-art logistics center through its subsidiary, Adjupharm GmbH, enhances its distribution capacity and operational capabilities in Germany, setting the stage for future growth.
IM Cannabis has announced the acquisition of a 51.3% stake in Oranim Plus Pharm Ltd., positioning the company as one of the largest medical cannabis retailers in Israel, with combined annualized revenues exceeding $44 million. Oranim, located in Jerusalem, generated approximately $16.5 million in revenue over the past year. The acquisition, valued at approximately NIS 11.94 million ($4.9 million), aims to enhance distribution capabilities and capitalize on market growth. The deal is expected to close by Q2 2022, pending necessary regulatory approvals.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announced that its recreational cannabis brand WAGNERS will be introduced in Israel following approval from the Israeli Ministry of Health for Focus Medical Herbs Ltd. to import premium cannabis from Trichome JWC Acquisition Corp. This move allows the import of an estimated 1,200 kilograms of cannabis throughout 2022. WAGNERS has shown significant market share growth in Canada, reaching 3.8% in Ontario. CEO Oren Shuster emphasized the strategic importance of this launch in enhancing the company's global supply chain and shareholder value.